ModerateVitamin K antagonist anticoagulants×Fixed-dose combination: aminopenicillin plus beta-lactamase inhibitor
Updated · Methodology
Mechanism
Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list amoxicillin among drugs that can potentiate acenocoumarol, and the generic SmPC also lists amoxicillin with clavulanic acid (AEMPS). According to the amoxicillin/clavulanic acid SmPC, oral anticoagulants and penicillins have been widely used together without reported interactions. The literature, however, contains cases of a raised INR in people taking warfarin or acenocoumarol who started amoxicillin. The documents do not explain how this happens (AEMPS). Prolonged prothrombin time has also been reported rarely in people treated with amoxicillin/clavulanic acid (AEMPS). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding. The literature reports a raised international normalised ratio (INR) in people taking warfarin or acenocoumarol who started amoxicillin. Prolonged bleeding time and prothrombin time also appear among the adverse effects of amoxicillin/clavulanic acid itself (amoxicillin/clavulanic acid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. If amoxicillin/clavulanic acid is needed, check the prothrombin time or the international normalised ratio (INR) carefully after the antibiotic is started and after it is stopped. Adjust the acenocoumarol dose to keep the desired level of anticoagulation (amoxicillin/clavulanic acid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; amoxicillin/clavulanate prescribing information, US Food and Drug Administration, FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped, including after the end of the antibiotic course (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Amoxicilina/ácido clavulánico, Augmentine 500 mg/125 mg (nº registro 81482), secciones 4.4 y 4.5 (2024)– AEMPS, CIMA, nº registro 81482 (Augmentine 500 mg/125 mg comprimidos recubiertos con película, GlaxoSmithKline; mismo texto sobre anticoagulantes orales en 4.5 de Augmentine suspensión, nº 59051, y sobres, nº 56683), revisión 07/2024, secciones 4.4, 4.5 y 4.8
- FDA: Augmentin ES-600 (amoxicillin and clavulanate potassium) prescribing information (2026)– FDA, DailyMed setid 59979859-8c9b-4173-a5e3-2e6312fd9d79 (USAntibiotics), versión 6, 07/2026, secciones 4 y 7.2